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Teriflunomide is an oral disease-modifying therapy recently approved in several locations
for relapsing-remitting multiple sclerosis. To gain insight into the effects of terifluno-
mide, immunocyte population changes were measured during progression of experi-
mental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide
attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and
neutrophils.Teriflunomide also mitigated the disease-induced changes in immune cell pop-
ulations in the blood and spleen suggesting an inhibitory effect on pathogenic immune
responses.
Keywords: multiple sclerosis, teriflunomide, experimental autoimmune encephalomyelitis, lymphocytes,
dihydro-orotate dehydrogenase
INTRODUCTION
Teriflunomide is a novel oral immunomodulatory drug recently
approved in several locations as a disease-modifying treatment for
relapsing-remitting multiple sclerosis (RRMS) (1). Immune cell
activation and proliferation, which are critical for the progression
of autoimmune diseases such as MS, are dependent on de novo
pyrimidine synthesis (2), and extensive in vitro studies have shown
that teriflunomide is a selective and reversible inhibitor of mito-
chondrial dihydro-orotate dehydrogenase (DHO-DH) (3), the key
enzyme involved in this process (4, 5). Teriflunomide reversibly
arrests cells in the G1 phase of the cell cycle (6) and slowly dividing
or resting cells, which rely on the salvage pathway for pyrimidine
synthesis, are relatively unaffected. Teriflunomide has been shown
to have a cytostatic effect on proliferating T and B lymphocytes
(7), but further in vivo studies are necessary to characterize its
therapeutic effects and mechanism of action more fully.
Experimental autoimmune encephalomyelitis (EAE) is a well-
studied animal model of human MS (8, 9). EAE is induced
by injecting susceptible animals with central nervous system
(CNS) extract, purified myelin components, or synthesized spe-
cific peptides [derived from myelin oligodendrocyte glycopro-
tein (MOG), proteolipid protein (PLP), or myelin basic pro-
tein (MBP)] emulsified in an adjuvant (10–12). The Dark
Agouti (DA) rat model of EAE mimics certain aspects of
the clinical course of disease in people with RRMS (9), typ-
ified by progressive, sustained demyelination, and associated
axonal loss (13–15). In the DA rat model of EAE, neurolog-
ical impairments, manifesting as a flaccid tail, are observed
at disease onset, followed by an acute attack with disturbed
gait and paresis/paralysis. Most animals recover from paralysis
and experience remission, but then may undergo one or more
relapses (10).
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The neurological impairment in EAE is mediated by activa-
tion of autoimmune responses and is accompanied by infiltration
of activated T cells, B cells, natural killer (NK) cells, and mono-
cytes into the affected CNS tissue (10, 16). The development
and progression of EAE are reduced by certain immunomodula-
tory drugs, corticosteroids, cytokines, chemokines, and cells with
anti-inflammatory functions, such as regulatory T cells and spe-
cific monocyte subtypes (17–23). Teriflunomide has been shown
to ameliorate EAE disease severity by reducing inflammation,
demyelination, and axonal loss in the cervical spinal cord in the
DA rat model (24). However, changes in circulating and tissue-
associated specific immune cell subtypes in the presence or absence
of teriflunomide have not yet been well characterized.
To gain further insight into the therapeutic effects of terifluno-
mide treatment, a preclinical study was performed in the DA rat
model of EAE. The aim of this study was to characterize the effects
of teriflunomide on immune cell numbers and distribution during
EAE progression.
MATERIALS AND METHODS
STUDY DESIGN
To measure the effects of teriflunomide on different immune cell
populations in the DA rat EAE model, a therapeutic treatment
design was used with negative and positive controls. Animals were
assigned to undergo EAE induction (n= 131) or to remain naïve
to immunization and receive vehicle sham treatment (negative
control; n= 39). Animals that showed signs of EAE were ran-
domly assigned to receive once-daily oral treatment with vehicle
(positive control; n= 45) or teriflunomide (10 mg/kg) (treatment
group; n= 45) until study end. Negative control animals received
the same daily handling as EAE-induced animals, and received
vehicle orally on a once-daily basis.
EXPERIMENTAL ANIMALS AND EAE INDUCTION
This study was carried out in accordance with an animal use
protocol approved by the Institutional Animal Care and Use
Committee (25).
Healthy, male, 6-week-old DA rats (Harlan Laboratories, Indi-
anapolis, IN, USA) were housed three to a cage in a room main-
tained at 23± 2°C with a relative humidity of 50% and a 12-h
light cycle. They were allowed ad libitum access to a commer-
cial diet (Harlan Teklad 2016, Harlan Laboratories, Madison, WI,
USA) and filtered water, and were acclimated to the facility for 2–
4 weeks prior to study initiation. At study initiation, animals were
8–10 weeks of age and weighed between 162 and 242 g.
Experimental autoimmune encephalomyelitis was induced by
immunization with a single 0.2 mL intradermal/subcutaneous
injection of an encephalitogenic inoculant emulsion [rat spinal
cord homogenate 50% (w/v) in saline mixed with an equal vol-
ume of Complete Freund’s Adjuvant containing Mycobacterium
tuberculosis 7 mg/mL] at the base of the tail (24). Pertussis toxin
was not used in the induction of EAE. Beginning 5 days post-
inoculation, neurological scores in immunized rats were assessed
daily in an unblinded fashion. Clinical disease was scored for typi-
cal signs according to the following scale: 0= normal; 0.5= partial
loss of tail tone; 1= complete tail atony; 2= complete tail atony
with hindlimb weakness; 2.5= hindlimbs weak; 3= hindlimb
paresis; 3.5= hindlimb paresis with one leg completely para-
lyzed; 4= complete paralysis; 4.5=moribund state; 5= death due
to EAE.
COMPOUND ADMINISTRATION
On the first day of disease onset (functional deficit score ≥1),
immunized rats received their first dose of teriflunomide [sus-
pended in vehicle: carboxymethylcellulose made up to 0.06% (w/v)
in water, to which Tween 80 was added to reach a final concentra-
tion of 0.5% (v/v)] or vehicle only. Teriflunomide was formulated
daily at a concentration of 10 mg/mL. Rats were dosed by oral
gavage at a volume of 1.0 mL/kg. This yielded an effective dose of
10 mg/kg. Negative control (naïve) animals received their first oral
dose of vehicle on the same day as corresponding immunized rats.
Oral treatment continued once daily for all animals until sacrifice
for sampling.
SAMPLING
Animals were allocated to one of four groups for sampling, accord-
ing to EAE stage reached in the positive controls: (1) disease onset
(functional deficit score of ≥1); (2) acute attack (score of 3 or
4 for two consecutive days); (3) remission (drop of ≥1 score for
two consecutive days); (4) relapse (increase of ≥1 full score from
the trough of remission for two consecutive days). Each group
contained 10–15 rats. Tissue samples (blood, cervical spinal cord,
and spleen) were collected for analysis at each stage. To keep sam-
ple selection unbiased, when each positive control (immunized,
vehicle-treated) rat reached the required disease stage and was sac-
rificed, one negative control (naïve, vehicle-treated) rat and one
teriflunomide-treated rat were also sacrificed. The negative control
group was used for baseline measurements at each disease stage.
On the day of sampling, rats were euthanized with CO2 and
blood was collected via cardiac puncture. A 600µL aliquot of
whole blood was taken and analyzed on the Advia 120 automated
cell counter (Siemens Healthcare Diagnostics, Newark, DE, USA)
to determine total cell counts of basophils, eosinophils, lympho-
cytes, monocytes, neutrophils, and white blood cells (WBCs). Rat
peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood by Ficoll-Hypaque density gradient centrifugation,
using Histopaque® 1077 (Sigma, St. Louis, MO, USA), followed by
a red cell lysis procedure using Ammonium-Chloride-Potassium
(ACK) lysis buffer. PBMCs were suspended in staining buffer (BD
Biosciences, San Jose, CA, USA) and stored at+4°C until antibody
staining for flow cytometry.
Spinal cords were fluid-perfused out of excised spinal columns
with phosphate-buffered saline (PBS) and the cervical region dis-
sected from the full-length spinal cord. Cells from the spinal cord
were isolated by gently grinding the tissue through a 70µm cell
strainer, followed by washing and filtering out debris through a
clean cell strainer. Filtered cells were centrifuged and re-suspended
in staining buffer at 1× 107 cells/mL and the samples were stored
at+4°C until use.
Spleens were excised and weighed. Splenocytes were isolated as
described above for the spinal cord preparations, followed by a red
cell lysis procedure using ACK lysis buffer. Cells were re-suspended
in staining buffer at 1× 107 cells/mL and the samples were stored
at+4°C until use.
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HISTOPATHOLOGICAL EVALUATION
Tissue and section preparation
A 2 mm cervical spinal cord sample from each animal was
immersed in 10% (w/v) buffered formalin for 48 h at+4°C before
being transferred into PBS. Samples were processed and embedded
into paraffin blocks, each block containing 16–20 cervical cords
from different treatment groups. Twenty 5µm sections were pre-
pared from each block and mounted onto Super Frost® Plus glass
slides (Menzel-Gläser, Braunschweig, Germany).
Histology and immunohistochemistry
Immunohistochemistry to evaluate inflammatory cell subtypes
was performed on the automated Discovery XT instrument, using
the DAB Map™ detection kit (Ventana Medical Systems, Tucson,
AZ, USA). Overall, inflammatory cell distribution was assessed
with hematoxylin and eosin staining (Rowley Biochemical Insti-
tute, Inc., Danvers, MA, USA). Demyelination was evaluated with
Luxol® fast blue staining (Rowley Biochemical Institute Inc., Dan-
vers, MA, USA). T cells were stained with anti-CD3 antibody
(Invitrogen Zymed, San Francisco, CA, USA), and macrophages
and microglia were stained with anti-Iba1 antibody (Wako Chem-
icals USA Inc., Richmond, VA, USA). CD3 and Iba1 antibody-
stained slides were scanned with the Aperio scanner (Aperio Tech-
nologies, Vista, CA, USA); digital images were analyzed with Ape-
rio algorithms for total number of CD3+ cells and total percentage
(relative to spinal cord area) of positive staining by anti-Iba1 anti-
body. Neutrophils were stained with anti-myeloperoxidase anti-
body (Abcam, Cambridge, MA, USA); myeloperoxidase antibody-
stained slides were assessed for staining and then scored visually
in a semi-quantitative manner.
FLOW CYTOMETRY ANALYSIS
To assess lymphocyte composition, 1× 106 cells were re-
suspended in staining buffer and stained for cell-surface markers
with fluorescent dye-conjugated antibodies (all from BD Bio-
sciences, San Diego, CA, USA). Cell samples were analyzed on
the FACSCalibur®(BD, Franklin Lakes, NJ, USA) flow cytometer
using Cell Quest™ Pro software version 5.2.
In all samples, purified mouse immunoglobulin (Ig)G1 anti-
rat CD32 (clone D34-485) was used (1µg/million cells) to block
non-specific binding to the high-affinity IgG binding receptor, Fc
gamma RII. The proportions of CD3+, CD4+, and CD8+ posi-
tive T cells in splenocytes, cervical spinal cord cells, and PBMCs
were determined by staining cells with mouse IgM anti-rat CD3
allophycocyanin (APC; clone 1F4), mouse IgG2a anti-rat CD4 R-
phycoerythrin (PE; clone OX-35), and mouse IgG1 anti-rat CD8α
peridinin-chlorophyll (PerCP; clone OX-8). Unstained cells and
cells stained with the corresponding isotype fluorescent antibod-
ies mouse IgM APC (clone G155-228), mouse IgG2a PE (clone
G155-178), and mouse IgG1 PerCP (clone MOPC-31C) were used
as controls for calibrating the instrument and gating positive cells.
For analysis of lymphocytes, a canonical “lymphocyte gate,” based
on forward and side scatter (FSC/SSC) was drawn to distinguish
the lymphocyte population from larger and more granular cells.
The lymphocyte gate was adjusted for each tissue type throughout
the experiment to adjust for differences in lymphocyte cell size and
granularity and to eliminate contaminating debris.
Relative percentages of T cells, B cells, and NK cells within the
lymphocyte population in splenocytes, cervical spinal cord, and
PBMCs were assessed by staining with a rat T-cell, B-cell, NK-cell
(T/B/NK) cocktail: mouse IgM anti-rat CD3 APC (clone 1F4),
mouse IgG1 anti-rat CD45RA fluorescein isothiocyanate (FITC;
clone OX-33), and mouse IgG1 anti-rat CD161a PE (clone 10/78).
Unstained cells and cells stained with the Ig Isotype Control Cock-
tail – A: mouse IgG1 FITC (clone MOPC-21), mouse IgG1 PE
(clone MOPC-21), and mouse IgM APC (clone G155-228) were
used as controls for calibrating the instrument and gating positive
cells.
STATISTICAL ANALYSIS
Mean and standard error of the mean values were calculated per
group at each disease stage for each variable: neurological score;
spleen weight; total cell counts in whole blood; and flow cytometry
percentage of gated cells. Proportions of CD3+ T cells, CD45RA+
B cells, and CD161a+ NK cells were calculated as a percentage of
total lymphocytes. Proportions of CD4+ and CD8+ T cells were
calculated as a percentage of CD3+ T cells. Out of 170 animals
(131 inoculated and 39 naïve), 21 (12%) had some or all samples
not available for flow cytometry analysis.
For each variable at each stage, two comparisons were of
interest: (1) negative control (naïive) vs. positive control (EAE-
induced), to validate the disease model; (2) positive control vs.
teriflunomide, to assess treatment effect. No comparison was
made between teriflunomide and negative control groups. Com-
parisons of interest were conducted using a parametric or non-
parametric two-way analysis of variance (ANOVA) with treatment,
day, and treatment× day interaction as factors. Specifically, two-
way ANOVA with a common variance was used if assumptions
regarding normality of distribution and equal variance were satis-
fied; two-way ANOVA adjusted for unequal variances was used if
only the normality assumption was satisfied; and non-parametric
two-way ANOVA was used if the normality assumption was not
satisfied. Immunohistochemistry data at each disease stage for
each endpoint were analyzed using a non-parametric one-way
ANOVA model. Analyses were carried out using SAS® version 9.2
(SAS, Cary, NC, USA).
RESULTS
NEUROLOGICAL SCORES AND SPINAL CORD ANALYSIS
Dark Agouti rats immunized with spinal cord homogenate devel-
oped EAE symptoms with characteristic disease onset, acute attack,
remission, and relapse stages. In comparison, rats treated with
teriflunomide from the time of disease onset developed reduced
levels of neurological deficits vs. vehicle-treated rats, and achieved
durable remission (Figure 1).
Immunohistochemical analysis of the spinal cord indicated that
EAE induction was associated with significant infiltration of CD3+
T cells and Iba1+ macrophages/microglia at all four disease stages
(Figures 2 and 3A,B; Table 1), and with spinal cord infiltration of
myeloperoxidase-positive neutrophils at acute attack and relapse
(Figure 3C; Table 1). At onset, prior to infiltration and administra-
tion of teriflunomide or vehicle, binding of neutrophils to spinal
cord endothelium was readily apparent in EAE-induced animals
(Figure 3D). Teriflunomide significantly attenuated spinal cord
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FIGURE 1 | Neurological deficit scores in teriflunomide-treated and
control Dark Agouti EAE rats. EAE was induced by immunization with
spinal cord homogenate. Animals showing signs of EAE were assigned
to receive daily oral teriflunomide (10 mg/kg) or vehicle from the first
day of disease onset (functional deficit score ≥1, labeled as day 0)
throughout the study until sacrifice for sampling, and neurological
scores were assessed daily. Cohorts (10–15 animals per treatment
group per time point) were sacrificed at onset (day 0), acute attack (day
5), remission (day 9), and relapse (day 13), according to the disease
stage of EAE-vehicle-treated rats. Scoring key: 0=normal;
1= complete tail atony; 2= complete tail atony with hindlimb
weakness; 3=hindlimb paresis; 4= complete paralysis; 5=death due
to EAE. EAE, experimental autoimmune encephalomyelitis; SEM,
standard error of the mean.
infiltration of CD3+ T cells and Iba1+ macrophages/microglia at
all three treatment phases of the disease (Figure 2; Table 1) and
also significantly attenuated increases in myeloperoxidase-positive
neutrophils at acute and remission phases (Figure 3C; Table 1).
The inhibitory effect of teriflunomide treatment on the extent
of inflammatory immune cell infiltration observed histologically
within the spinal cord was also corroborated by flow cytometry
analysis of cells isolated from the spinal cord at different stages of
disease. As with the immunohistochemical observations, EAE was
associated with increases in inflammatory cells, shown by the num-
bers of CD3+ T cells and CD161a+ NK cells recovered from the
spinal cord at acute attack, remission, and relapse. The increases
in both of these cell types were attenuated by teriflunomide
(Figure 4).
Overall, these findings indicate a correlation between terifluno-
mide disease control and inhibition of inflammation within the
spinal cord.
PERIPHERAL CHANGES IN IMMUNE CELL COUNTS
Changes occurring in the periphery during the course of teri-
flunomide treatment were also investigated in terms of total cell
counts and proportions of various immune cell populations. At
a gross level, induction of EAE was associated with reductions in
spleen weight at acute attack, remission, and relapse; teriflunomide
treatment attenuated these weight reductions (Table 2). In whole
blood, disease-associated changes in immune cell populations
(basophils, eosinophils, lymphocytes, monocytes, neutrophils, and
WBCs) were observed; the effects of teriflunomide treatment on
these changes are detailed in Table 3.
Basophils were reduced at acute attack in EAE-induced ani-
mals compared with naïve animals, but were not significantly
different at other disease stages. Teriflunomide attenuated the
disease-associated basophil elevation at acute attack and had no
effect on levels at remission and relapse.
Circulating eosinophil levels showed a biphasic alteration in
EAE-induced animals, with a reduction at acute attack followed
by elevation during remission and relapse. Teriflunomide did not
alter the disease-associated reduction at acute attack, but did atten-
uate the disease-associated elevations at remission and relapse.
An insignificant trend toward reduced lymphocyte (T- and B-
cell) counts in EAE-induced animals occurred at disease onset,
progressing to significant reductions at acute attack, remission,
and relapse. Teriflunomide significantly attenuated the reductions
in circulating lymphocytes at acute attack and relapse. In con-
trast, at remission, circulating lymphocyte counts showed a greater
reduction in the teriflunomide group than in the EAE group.
Circulating monocyte counts were significantly increased at the
peak disease stages of acute attack and relapse in EAE-induced ani-
mals. Both stages of elevations were attenuated by teriflunomide.
At remission, monocyte counts were similar in EAE and naïve
animals, but were significantly lower in the teriflunomide-treated
animals.
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FIGURE 2 | Numbers of T cells and percent positive staining for
microglial cells by immunohistochemistry in cervical spinal cord
sections from EAE rats. Automated digital image analysis of inflammatory
cell populations in immunohistochemistry stained tissue sections of
cervical spinal cord from untreated and EAE rats (vehicle and
teriflunomide-treated) sacrificed at the indicated disease stages (onset,
acute attack, remission, relapse). n=5–10 animals per treatment group per
disease stage. (A) T cells identified with anti-CD3 antibody staining (B)
microglial cells (macrophages) identified with anti-Iba1 antibody staining.
Percent positive staining for microglial cells and cell counts per area for CD3
are shown. *p<0.005 vs. comparison group (EAE-vehicle vs. untreated;
EAE-teriflunomide vs. EAE-vehicle). EAE, experimental autoimmune
encephalomyelitis; SEM, standard error of the mean.
Disease-associated elevations in circulating neutrophils were
observed at all four stages of disease. Following disease onset, when
treatment was initiated, disease-associated neutrophil elevations
were significantly attenuated by teriflunomide.
Total WBC counts were elevated in EAE-induced animals vs.
naïve animals at disease onset and remission, with no significant
change at acute attack or relapse. Teriflunomide treatment had an
early effect of reducing disease-associated elevations in WBCs at
acute attack and remission disease stages, but did not have an effect
at the later relapse stage.
Overall, teriflunomide treatment tended to normalize immune
cell changes induced by the disease process.
PERIPHERAL IMMUNE CELL POPULATION DYNAMICS
The impact of teriflunomide treatment on immune cell population
dynamics in the spleen and blood was analyzed by flow cytometry.
In the spleen, reductions in CD3+ T cells (as a percentage of total
lymphocyte populations, measured by two independent antibody
detection methods) occurred in EAE-induced animals at disease
onset, acute attack, and relapse (Tables 4 and 5). A reduction
was also observed at remission, reaching significance in the T-cell
panel (Table 4) although not in the T/B/NK panel (Table 5). In
both assay methods, teriflunomide showed a non-significant trend
of attenuating disease-associated T-cell reductions at acute attack
and remission, and a significant attenuation at relapse (Tables 4
and 5). Increases in the percentage of CD4+ T cells and decreases
in the percentage of CD8+ T cells were observed in EAE-induced
animals at all four disease stages. Teriflunomide attenuated these
changes at acute attack and remission, but not at relapse (Table 4).
Induction of EAE was associated with significant reductions in
CD45RA+ B cells (as a percentage of total lymphocytes) at acute
attack and relapse, with a non-significant decrease observed at
remission. Disease-associated reductions in CD45RA+ B cells were
attenuated by teriflunomide at acute attack and relapse, whereas
the proportion of CD45RA+ B cells was lower in the teriflunomide
group than in the EAE group at remission (Table 5).
Percentages of CD161a+NK cells were increased at acute attack,
remission, and relapse in EAE-induced animals; teriflunomide
attenuated the observed increases at acute attack and relapse, but
not at remission (Table 5).
In PBMCs, in the T-cell subset and T/B/NK panel, disease-
associated reductions in the percentage of CD3+ T cells were seen
at onset, acute attack, and relapse, but not at remission. Teri-
flunomide attenuated the reductions at acute attack and relapse
(Figure 5B; Table 6). Increases in the percentage of CD4+ T cells,
and decreases in the percentage of CD8+ T cells, were observed at
all four disease stages. Teriflunomide attenuated these changes at
remission only (Table 6).
Induction of EAE was associated with reductions in the propor-
tions of CD45RA+ B cells at acute attack, remission, and relapse.
Teriflunomide treatment reduced B-cell levels further at acute
attack, but attenuated disease-associated reductions at remission
and relapse (Figure 5A). The percentage of CD161a+ NK cells was
increased at all four disease stages, and teriflunomide attenuated
the increases at all three treatment stages of acute attack, remission,
and relapse (Figure 5C).
DISCUSSION
In this study, we profiled immunological changes in a rat model
of RRMS, focusing on immunocytes in the cervical spinal cord,
circulation, and spleen during early onset, acute attack, remis-
sion, and relapse disease stages. To improve our understanding of
the impact that teriflunomide may have on inflammatory disease
processes in patients with MS, we further investigated how ther-
apeutic treatment with teriflunomide, beginning at disease onset,
affected immunocyte profiles during EAE disease progression. To
our knowledge, this preclinical study is the first to examine the
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FIGURE 3 | Staining of CD3+ T cells (A), Iba1+ macrophages/
microglia (B), and myeloperoxidase-positive neutrophils (C,D) in
cervical spinal cord sections from EAE rats. Representative images of
immunohistochemistry stained tissue sections used to evaluate
inflammatory cell populations in cervical spinal cord from EAE rats
(vehicle and teriflunomide-treated) sacrificed at the indicated disease
stages (onset, acute attack, remission, relapse). (A–C): upper panels
show stained sections of vehicle-treated EAE rats, lower panels show
stained sections of teriflunomide-treated EAE rats. Left boxed corner of
each panel shows enlargement. Anti-CD3 antibody staining identified T
cells (A), anti-Iba1 antibody staining identified microglial cells
(macrophages) (B), and myeloperoxidase staining identified neutrophils
(C). (D) Cervical spinal cord from disease onset in EAE rat stained with
myeloperoxidase to identify neutrophils. Arrowheads on the enlarged
section of (D) indicate neutrophils. EAE, experimental autoimmune
encephalomyelitis.
effect of teriflunomide on peripheral and CNS immune cell pop-
ulation changes during acute attack, remission, and relapse in the
DA rat model of EAE.
The immunological observations in the DA rat model of EAE
correlate with known immunopathological changes in MS (10,
24, 26). In this model, spinal cord infiltration of inflammatory
effector cells (22, 27), elevation of CD4+ T cells and reduction
in CD8+ T cells in the spleen (18, 20, 28), and early resistance to
apoptosis of invading cells (28) may all be key mediators of disease
onset and progression. Early neutrophil involvement has also been
reported as necessary for EAE progression (29–31). Similarly, MS
development and progression are thought to involve immunolog-
ical changes leading to inflammatory demyelination and axonal
loss (13), with putative pathophysiological roles for mitochondr-
ial dysfunction, T-cell infiltration into the CNS, and resistance to
apoptosis (14). Moreover, patients with MS have high numbers
of neutrophils in a primed state compared with subjects without
MS (32, 33).
As expected from earlier studies with DA rats (10, 24), EAE
induction was associated with the onset of progressive neuro-
logical impairment and influx into the spinal cord of T cells
and macrophages and, as shown in this report, NK cells and
Frontiers in Neurology | Multiple Sclerosis and Neuroimmunology October 2013 | Volume 4 | Article 169 | 6
Ringheim et al. Immunocyte effects of teriflunomide
Table 1 |Total number of CD3+ T cells, total percentage of Iba1+
macrophages/microglia, and myeloperoxidase-positive neutrophils in
cervical spinal cord in each treatment group at each disease stage.
Cell type Mean (SEM)
Disease
stage
Negative control
(naïve+vehicle)
Positive control
(EAE+vehicle)
Teriflunomide
(EAE+ treatment)
CD3+ T cells (in cervical spinal cord)
Onset 2.7 (0.3) 10.8 (2.3)† n/a
Acute attack 2.8 (0.4) 175.7 (35.8)‡ 17.6 (4.9)‡
Remission 3.6 (0.4) 104.2 (16.8)‡ 33.0 (5.3)‡
Relapse 2.9 (0.3) 141.9 (13.7)‡ 9.9 (2.7)**
Iba1+ macrophages/microglia (in cervical spinal cord)
Onset 7.4 (0.2) 8.7 (0.5)* n/a
Acute attack 7.0 (0.2) 36.3 (4.3)‡ 17.0 (2.8)**
Remission 7.4 (0.1) 41.5 (2.7)‡ 27.9 (2.3)**
Relapse 6.9 (0.2) 38.5 (4.8)‡ 11.8 (1.0)†
Myeloperoxidase-positive neutrophils (in cervical spinal cord)
Onset 0.3 (0.3) 0.1 (0.1) n/a
(EAE, no vehicle)
Acute attack 0 (0) 1.8 (0.4)‡ 0.3 (0.2)**
Remission 0 (0) 0.5 (0.2)* 0.1 (0.1)
Relapse 0 (0) 2.4 (0.6)‡ 0 (0)‡
Myeloperoxidase-positive neutrophils (in blood vessels outside of
spinal cord)
Onset 0.4 (0.3) 1.8 (0.3)** n/a
(EAE, no vehicle)
Acute attack 0.2 (0.2) 2.1 (0.4)‡ 0.8 (0.3)**
Remission 0.1 (0.1) 1.1 (0.3)** 0.2 (0.1)*
Relapse 0 (0) 0.7 (0.2)** 0.6 (0.2)
EAE, experimental autoimmune encephalomyelitis; n/a, not assessed; SEM, stan-
dard error of the mean.
n=5–10 animals per treatment group per disease stage. Immunohistochemistry
based scoring data.
*p< 0.05, **p<0.01, †p<0.001, ‡p≤0.0001 vs. comparison group (positive
control vs. negative control; teriflunomide vs. positive control).
neutrophils. This association was most evident at the early onset
and acute attack disease stages. However, during the remission
and relapse stages (when neurological scores changed), numbers
of T cells, macrophages, and neutrophils remained elevated, while
NK-cell levels declined and remained low thereafter. This suggests
that behavioral deficits do not correlate strictly with immunocyte
numbers in the spinal cord at the later relapsing-remitting stages of
the disease; rather, functional or cell subtype changes within spe-
cific immunocyte populations likely play a more dominant role in
the observed behavioral and neurological pathology. Such vary-
ing roles within immune cell types for both the induction and
inhibition of EAE and MS have been described for T cells (34),
macrophages (35–37), and NK cells (38, 39).
Peripheral immunocyte population changes during EAE in the
DA rat have not been reported previously, therefore changes in
spleen and peripheral blood samples were assessed in the present
study. Spleen weights were unchanged at early onset, but were sig-
nificantly decreased at acute attack, remission, and relapse, when
FIGURE 4 | Number ofT cells and NK cells by flow cytometry in
cervical spinal cord from EAE rats. Flow cytometry analysis (cell counts
per 105 cells) of immune cell populations in cervical spinal cord from naïve
and EAE rats (vehicle and teriflunomide-treated) sacrificed at the indicated
disease stages (onset, acute attack, remission, relapse). n=10–15 animals
per treatment group per disease stage. (A) CD3+ T cells and (B) CD161a+
NK cells were identified by antibody staining. *p≤0.0002 vs. comparison
group (EAE-vehicle vs. untreated; EAE-teriflunomide vs. EAE-vehicle). EAE,
experimental autoimmune encephalomyelitis; LS, least squares; NK, natural
killer; SEM, standard error of the mean.
active behavioral deficits occurred. Changes in immunocyte com-
position during EAE progression in the spleen and blood were
strikingly similar. T cells as a percentage of total lymphocytes were
reduced, with a shift toward higher CD4+ and reduced CD8+
percentages at all four disease stages. NK cells as a percentage of
total cells were also elevated at all four disease stages, whereas
B cells were reduced at the most active disease phases of acute
attack and relapse. These changes in spleen and blood immunocyte
composition likely reflect mobilization of immunocytes during
disease, and although assessment of changes in activation state and
trafficking patterns were beyond the scope of the present study,
changes in T-cell activation, and trafficking patterns in spleen
and blood, have been reported in a monophasic EAE rat model
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Table 2 | Spleen weights in each treatment group at each disease
stage.
Disease
stage
Least-squared mean (SEM) spleen weight (mg)
Negative control
(naïve+vehicle)
Positive control
(EAE+vehicle)
Teriflunomide
(EAE+ treatment)
Onset 467.4 (21.5) 474.1 (18.5) n/a
Acute attack 464.8 (11.1) 347.6 (6.1)‡ 395.0 (9.6)†
Remission 513.6 (17.4) 417.4 (10.8)‡ 472.3 (10.6)**
Relapse 513.0 (9.2) 437.5 (9.7)* 511.2 (23.8)*
EAE, experimental autoimmune encephalomyelitis; n/a, not assessed; SEM, stan-
dard error of the mean.
n=10–15 animals per treatment group per disease stage.
*p<0.05, **p< 0.01, †p<0.001, ‡p<0.0001 vs. comparison group (positive
control vs. negative control; teriflunomide vs. positive control).
(40). As mentioned, through its inhibition of DHO-DH, terifluno-
mide exerts a cytostatic effect on stimulated lymphocytes (7). In
a study of human PBMCs stimulated in vitro, Li et al. showed
that teriflunomide principally affected proliferation of lympho-
cytes, with little effect on function (41), and teriflunomide-treated
patients have been shown to mount effective responses to sea-
sonal influenza vaccination (42). In an adoptive transfer model
of EAE, in vitro teriflunomide treatment of MBP-specific T cells
prior to transfer reduced maximal disease scores in recipient naïve
animals. In vitro testing of the same teriflunomide-treated MBP-
specific T cells showed defects in antigen-induced proliferation,
but only modest functional impairment (43). These studies indi-
cate that teriflunomide-treated cells retain functionality in vivo.
Therefore, we might expect that the changes we observed in lym-
phocyte populations in teriflunomide-treated animals arise as a
consequence of diminished proliferation, rather than impaired
activation. Confirmatory studies to this effect would be of great
interest.
Teriflunomide treatment, initiated at the time of disease onset,
suppressed neurological deficit progression in EAE-induced DA
rats. Other studies in animal models have shown that terifluno-
mide can also ameliorate or prevent the emergence of symp-
toms consistent with MS when animals are dosed at remission
or prophylactically (24, 44). Studies in patients have also shown
therapeutic benefits for patients with relapsing forms of MS,
including subgroups with both higher and lower disease activ-
ity (45, 46). Taken together, this suggests that teriflunomide
is effective whenever it is administered in a relapsing disease
course, though future studies in animal models may contribute
to an understanding of the optimal point in disease course to
begin teriflunomide treatment. The improvement in neurological
deficits we observed during teriflunomide treatment was associ-
ated with reduced levels of spinal cord-infiltrating T cells, NK cells,
macrophages, and neutrophils, and with attenuation of disease-
associated changes in circulating lymphocytes, NK cells, and neu-
trophils. Teriflunomide also attenuated the EAE-associated reduc-
tion in spleen weight, elevations of circulating monocytes at acute
attack and relapse, and increased ratios of CD4+/CD8+ T cells in
Table 3 |Total cell counts in whole blood in each treatment group at
each disease stage.
Cell type and
disease stage
Least-squared mean (SEM) cell count (×103/µL)
Negative control
(naïve+vehicle)
Positive control
(EAE+vehicle)
Teriflunomide
(EAE+ treatment)
Basophils
Onset 0.053 (0.013) 0.073 (0.012) n/a
Acute attack 0.067 (0.005) 0.018 (0.004)‡ 0.046 (0.005)†
Remission 0.053 (0.006) 0.049 (0.005) 0.063 (0.007)
Relapse 0.051 (0.004) 0.058 (0.006) 0.054 (0.004)
Eosinophils
Onset 0.071 (0.017) 0.106 (0.005) n/a
Acute attack 0.095 (0.011) 0.041 (0.004)‡ 0.048 (0.003)
Remission 0.064 (0.009) 0.120 (0.010)† 0.070 (0.007)†
Relapse 0.102 (0.013) 0.155 (0.011)** 0.082 (0.011)‡
Lymphocytes
Onset 6.626 (1.125) 4.401 (1.182) n/a
Acute attack 7.613 (0.317) 2.317 (0.194)‡ 3.525 (0.157)†
Remission 6.277 (0.472) 4.397 (0.153)* 3.907 (0.125)*
Relapse 8.583 (0.474) 3.802 (0.275)‡ 5.709 (0.213)**
Monocytes
Onset 0.114 (0.038) 0.316 (0.065) n/a
Acute attack 0.102 (0.010) 0.349 (0.042)‡ 0.153 (0.016)‡
Remission 0.314 (0.147) 0.437 (0.025) 0.146 (0.013)‡
Relapse 0.145 (0.008) 0.299 (0.016)‡ 0.197 (0.021)**
Neutrophils
Onset 0.996 (0.109) 8.875 (0.590)‡ n/a
Acute attack 1.057 (0.084) 6.511 (0.933)** 2.611 (0.261)**
Remission 0.919 (0.072) 6.855 (0.432)‡ 4.002 (0.438)‡
Relapse 1.432 (0.031) 8.050 (0.394)‡ 5.278 (0.539)**
Total white blood cells
Onset 8.096 (1.344) 14.074 (1.451)* n/a
Acute attack 9.029 (0.373) 9.331 (1.041) 6.454 (0.287)*
Remission 7.745 (0.548) 12.002 (0.572)‡ 8.314 (0.468)‡
Relapse 10.423 (0.349) 12.491 (0.521) 11.441 (0.743)
EAE, experimental autoimmune encephalomyelitis; n/a, not assessed; SEM, stan-
dard error of the mean.
n=10–15 animals per treatment group per disease stage. Cell counts were mea-
sured using an ADIVA automated cell count system.
*p<0.05, **p<0.01, †p<0.001, ‡p≤0.0001 vs. comparison group (positive
control vs. negative control; teriflunomide vs. positive control).
the spleen at acute attack and remission. These treatment effects
of teriflunomide, administered after disease onset, suggest that
its therapeutic activity may be due to an inhibitory effect on
immune cell proliferation and recruitment and, potentially, on
transmigration.
Reductions in T-cell, NK-cell, and neutrophil spinal cord infil-
tration may be partly responsible for the corresponding neurolog-
ical benefits of teriflunomide treatment. Teriflunomide treatment
significantly reduced the numbers of T cells and NK cells infil-
trating the cervical spinal cord at all stages of EAE progression,
with the lowest levels observed at remission and relapse. Reduced
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Table 4 | Proportiona of CD3+, CD4+, and CD8+ T cells in spleen in
each treatment group at each disease stage.
Cell type Least-squared mean (SEM) percentage
Disease
stage
Negative control
(naïve+vehicle)
Positive control
(EAE+vehicle)
Teriflunomide
(EAE+ treatment)
CD3+ T cells
Onset 42.38 (0.92) 37.92 (1.00)* n/a
Acute attack 46.55 (1.32) 40.13 (2.01)** 42.72 (1.29)
Remission 50.35 (0.30) 45.01 (1.45)** 47.91 (1.14)
Relapse 50.01 (1.03) 34.11 (2.00)‡ 43.40 (1.28)†
CD4+ T cells
Onset 62.19 (1.92) 70.24 (0.76)† n/a
Acute attack 70.96 (1.23) 77.92 (0.88)‡ 75.56 (0.48)*
Remission 72.94 (0.44) 80.06 (0.64)‡ 75.87 (0.58)‡
Relapse 71.53 (0.67) 75.23 (1.00)† 75.21 (0.51)
CD8+ T cells
Onset 32.57 (0.74) 26.67 (0.77)** n/a
Acute attack 26.17 (1.11) 19.17 (0.72)† 21.57 (0.47)*
Remission 24.26 (0.41) 17.26 (0.65)‡ 21.25 (0.57)§
Relapse 24.88 (0.42) 20.79 (0.59)‡ 21.88 (0.44)
EAE, experimental autoimmune encephalomyelitis; n/a, not assessed; SEM, stan-
dard error of the mean.
n=10–15 animals per treatment group per disease stage. Cell frequencies were
measured using flow cytometry.
aCD3+ T cells as a percentage of total lymphocytes; CD4+, and CD8+ T cells as a
percentage of CD3+ T cells.
*p< 0.05, **p<0.01, †p<0.001, ‡p<0.0001 vs. comparison group (positive
control vs. negative control; teriflunomide vs. positive control).
infiltration of T cells into the spinal cord has been shown to sup-
press EAE induction in mice (47). Notably, a higher CD4+/CD8+
T-cell ratio in the spinal cord may underlie enhanced EAE sus-
ceptibility in mice (48), and enhanced infiltration of NK cells
into the spinal cord may exacerbate EAE symptoms in DA rats
(49). As the observed reductions in T-cell, NK-cell, and neutrophil
spinal cord infiltration and neurological impairment progression
occurred after early effector-phase activation, teriflunomide may
potentially act to reduce the numbers of cells migrating to the CNS
and/or inhibit local expansion of infiltrating immunocytes. Teri-
flunomide’s effects on the proliferation of activated lymphocytes
are expected to lead to decreased CNS inflammation (50). T-cell
expansion within the CNS has been documented in the EAE model
(51), so it will be important for future studies to establish whether
teriflunomide affects the proliferation of T cells within the CNS
in addition to its effects on T-cell proliferation in the periphery
(41). Other immunomodulatory effects independent of pyrim-
idine synthesis that have been described for teriflunomide may
also account for the reduction in DA rat spinal cord immunocytes
observed in this study, including reduced T-cell chemotaxis (43),
inhibition of protein aggregation (52), and weakening of T-cell
interactions with antigen-presenting cells (53).
The prevention by teriflunomide of neutrophil spinal cord
infiltration may account for some of its therapeutic behavioral
benefit. Neutrophils, which are early responders to tissue damage,
Table 5 | Proportiona of CD3+ T cells, CD45RA+ B cells, and CD161a+
NK cells in spleen in each treatment group at each disease stage.
Cell type Least-squared mean (SEM) percentage
Disease
stage
Negative control
(naïve+vehicle)
Positive control
(EAE+vehicle)
Teriflunomide
(EAE+ treatment)
CD3+ T cells
Onset 35.78 (1.13) 31.03 (1.86)* n/a
Acute attack 35.55 (1.40) 31.07 (1.80)* 34.09 (1.16)
Remission 42.56 (2.32) 39.18 (1.39) 42.08 (1.85)
Relapse 43.23 (1.12) 32.85 (1.69)‡ 43.32 (0.97)‡
CD45RA+ B cells
Onset 37.01 (0.51) 36.08 (1.33) n/a
Acute attack 38.15 (0.72) 33.04 (1.01)‡ 36.79 (1.01)**
Remission 36.00 (1.68) 32.12 (1.15) 27.50 (0.77)**
Relapse 35.00 (0.56) 24.76 (0.57)‡ 29.56 (1.25)*
CD161a+ NK cells
Onset 11.46 (0.47) 13.09 (0.30) n/a
Acute attack 12.47 (0.49) 15.76 (0.36)† 13.19 (0.76)**
Remission 9.52 (0.33) 15.82 (0.77)‡ 16.41 (0.68)
Relapse 10.56 (0.49) 26.82 (1.60)‡ 14.23 (0.81)‡
EAE, experimental autoimmune encephalomyelitis; n/a, not assessed; NK, nat-
ural killer; SEM, standard error of the mean. Cell frequencies were measured
using flow cytometryn= 10–15 animals per treatment group per disease stage.
aAll cell types as a percentage of total lymphocytes.
*p<0.05, **p<0.01, †p<0.001, ‡p≤0.0001 vs. comparison group (positive
control vs. negative control; teriflunomide vs. positive control).
infiltrate the spinal cord early during the acute attack phase in
EAE (29) and are implicated in EAE disease progression (30,
31). They also contribute to early inflammatory processes impor-
tant in EAE pathology, such as the recruitment of CD4+ T
cells (54), CD8+ effector T-cell generation (55), and infiltra-
tion of inflammatory monocytes (31). Support for the role of
neutrophils in EAE has been demonstrated by selective deple-
tion of Gr-1+ neutrophils with antibodies (30). The effects of
these antibody treatments appear to be specific for neutrophil
depletion because susceptibility to EAE can be restored by injec-
tion of purified neutrophils (56). A role for neutrophils in
upstream regulation of macrophage infiltration is further sug-
gested by the effects of injecting activated neutrophil secre-
tion products into tissues of neutrophil-depleted animals, which
reverses the block in macrophage infiltration (31). Our data in
the DA rat EAE model demonstrated that teriflunomide treat-
ment only partially reversed the increases in circulating neu-
trophils at acute attack and remission (but not at relapse), while
spinal cord levels remained low at all disease stages. Thus, the
reduced number of circulating neutrophils cannot completely
account for the teriflunomide-associated reduction in spinal
cord neutrophils, indicating that teriflunomide may also reduce
neutrophil infiltration as part of its mechanism of action in
attenuating EAE.
Based on the results of this and other studies in the DA rat
model of EAE, teriflunomide has several potential CNS benefits
in MS. Teriflunomide may decrease infiltration of T and B cells
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FIGURE 5 | Proportion of circulating B,T, and NK cells by flow
cytometry in PBMCs from EAE rats. Flow cytometry analysis of immune
cell populations in PBMCs from blood taken from naïve and EAE rats
(vehicle and teriflunomide-treated) sacrificed at the indicated disease
stages (onset, acute attack, remission, relapse). n=10–15 animals per
treatment group per disease stage. CD45RA+ B cells (A), CD3+ T cells (B),
and CD161a+ NK cells (C) were identified by staining with an anti-rat
T/B/NK-cell antibody cocktail, and are shown as a percentage of total
lymphocytes. *p<0.05 vs. comparison group (EAE-vehicle vs. untreated;
EAE-teriflunomide vs. EAE-vehicle). EAE, experimental autoimmune
encephalomyelitis; LS, least squares; NK, natural killer; PBMCs, peripheral
blood mononuclear cells; SEM, standard error of the mean.
Table 6 | Proportiona of CD3+, CD4+, and CD8+ T cells, CD45RA+ B
cells, and CD161a+ NK cells in PBMCs in each treatment group at
each disease stage.
Cell type Least-squared mean (SEM) percentage
Disease
stage
Negative control
(naïve+vehicle)
Positive control
(EAE+vehicle)
Teriflunomide
(EAE+ treatment)
CD3+ T cells
Onset 58.03 (0.85) 40.67 (3.79)† n/a
Acute attack 60.37 (1.59) 38.84 (5.67)‡ 49.38 (1.91)*
Remission 57.69 (1.90) 52.99 (2.30) 54.75 (2.30)
Relapse 59.73 (0.83) 40.71 (2.95)‡ 60.84 (1.53)‡
CD4+ T cells
Onset 71.19 (0.93) 76.13 (1.24)† n/a
Acute attack 75.12 (0.63) 80.02 (1.01)‡ 78.84 (0.57)
Remission 76.10 (0.77) 81.59 (0.27)‡ 77.80 (0.64)‡
Relapse 73.07 (0.22) 75.72 (0.57)** 76.14 (0.28)
CD8+ T cells
Onset 24.78 (0.43) 19.90 (0.35)‡ n/a
Acute attack 21.86 (0.52) 16.42 (0.90)‡ 16.93 (0.74)
Remission 20.69 (0.67) 15.85 (0.30)‡ 19.00 (0.66)‡
Relapse 24.19 (0.23) 21.40 (0.55)** 21.82 (0.25)
CD45RA+ B cells
Onset 18.03 (0.96) 21.39 (0.79) n/a
Acute attack 13.06 (0.66) 7.40 (0.52)‡ 5.72 (0.40)*
Remission 12.90 (0.94) 6.26 (0.49)‡ 8.47 (0.52)**
Relapse 15.13 (0.47) 6.47 (0.54)‡ 8.43 (0.54)*
CD161a+ NK cells
Onset 14.10 (1.12) 27.79 (5.46)* n/a
Acute attack 18.80 (1.08) 45.72 (3.03)‡ 35.47 (2.65)**
Remission 21.12 (1.35) 35.00 (2.65)† 28.52 (2.05)*
Relapse 17.66 (1.24) 37.89 (3.03)‡ 19.18 (1.43)‡
EAE, experimental autoimmune encephalomyelitis; n/a, not assessed; NK, nat-
ural killer; PBMCs, peripheral blood mononuclear cells; SEM, standard error of
the mean. Cell frequencies were measured using flow cytometry.
n=10–15 animals per treatment group per disease stage.
aCD3+ T cells, CD45RA+ B cells, and CD161a+ NK cells as a percentage of total
lymphocytes; CD4+ and CD8+ T cells as a percentage of CD3+ T cells.
*p<0.05, **p<0.01, †p<0.001, ‡p≤0.0001 vs. comparison group (positive
control vs. negative control; teriflunomide vs. positive control).
into the spinal cord (via effects on proliferation and potentially
on migration), reduce demyelination and axonal damage/loss in
the cervical spinal cord, reduce neurodegeneration, and thereby
preserve conduction (24). These effects are consistent with the
clinical benefits of teriflunomide treatment observed in patients
with RRMS (45). In the Teriflunomide Multiple Sclerosis Oral
(TEMSO) trial, the first pivotal Phase III study to report findings
from the teriflunomide clinical development program, once-daily
oral teriflunomide 14 mg significantly reduced annualized relapse
rate by over 30% (p< 0.001 vs. placebo) and reduced risk of
12-week confirmed disability progression by 30% (p= 0.03 vs.
placebo) (45). The incidence of serious infections and malignan-
cies in teriflunomide groups was low and comparable to those
in the placebo group (45), suggesting that teriflunomide does
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not cause generalized immunosuppression or lymphocyte toxi-
city. Indeed, during prolonged teriflunomide exposure, the risk
of opportunistic infections is not increased and the incidence of
malignancies is comparable to that of the general population (57).
The results of this study both support and further character-
ize the effects of teriflunomide on the immune system. Changes
in immunocyte populations during disease progression in the DA
rat EAE model were attenuated by teriflunomide, suggesting its
clinical benefits in MS may be achieved via a modulatory effect on
a previously activated immune system. Teriflunomide-treated ani-
mals remained in remission, demonstrating that clinical benefits
may be achieved without complete negation of effector-cell acti-
vation. Further information is needed on the relative significance
of immunocyte populations and their specific functional impact
on the EAE model at different disease stages, and how specific
effects of treatment on these populations translate into clinical
benefits, in order to continue to build on our understanding of the
therapeutic action of teriflunomide.
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